COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease (Sirocco)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00501111
Recruitment Status : Completed
First Posted : July 13, 2007
Last Update Posted : July 23, 2014
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in future trials.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: AZD3480 Drug: Donepezil Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 659 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease
Study Start Date : July 2007
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Arm Intervention/treatment
No Intervention: 1
Active Comparator: 2
Drug: Donepezil
Other Name: Aricept

Experimental: 3
Drug: AZD3480
3 oral doses

Primary Outcome Measures :
  1. Change in ADAS-Cog [ Time Frame: assessed after 12 weeks treatment ]

Secondary Outcome Measures :
  1. Change in ADCS-CGIC, Computerized neurological test battery (CDR) and MMSE [ Time Frame: assessed after 12 weeks treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of informed consent from patient and caregiver
  • Clinical prognosis of probable Alzheimer's disease
  • Patient must have a caregiver visiting the patient at least three times weekly

Exclusion Criteria:

  • Significant neurologic disease or dementia other than Alzheimer's disease
  • Major depressive disorder, other major psychiatric disorder
  • Use of acetylcholinesterase inhibitor or memantine for treatment of Alzheimer's disease within 8 weeks prior to enrollment
  • Impaired vision and/or hearing making cognitive testing difficult

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00501111

Show Show 71 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: AstraZeneca AZD3480, Medical Science Director AstraZeneca

Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00501111    
Other Study ID Numbers: D3690C00010
EuDract 2007-00835-24
First Posted: July 13, 2007    Key Record Dates
Last Update Posted: July 23, 2014
Last Verified: July 2014
Keywords provided by AstraZeneca:
Alzheimer Type
Alzheimer Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents